UPCC 05818: A phase I/II study to evaluate the safety pharmacodynamics and efficacy of atezolizumab in combination with entinostat and bevacizumab in patients with advanced renal cell carcinoma
Enrolling By Invitation
99 years or below
All
Phase
2
5 participants needed
1 Location
Brief description of study
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: renal cancer
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829522
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
